PMID- 28360528
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 10
DP  - 2017
TI  - The association of weight loss with patient experience and outcomes in a 
      population of patients with type 2 diabetes mellitus prescribed canagliflozin.
PG  - 89-99
LID - 10.2147/DMSO.S129824 [doi]
AB  - OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by 
      being overweight or obese. This study used a patient survey to assess health, 
      satisfaction, and diabetes self-management in relation to weight management. 
      METHODS: A survey including the Current Health Satisfaction Questionnaire, 
      Diabetes Distress Scale, and Diabetes Treatment Satisfaction Questionnaire was 
      administered using an online platform to a sample of 205 patients with T2DM 
      prescribed canagliflozin. Patients were placed into 5 groups based on their 
      self-reported weight change since initiation of canagliflozin: Lost >10 lbs, Lost 
      5-10 lbs, Lost <5 lbs, No Change, and Gained Weight. One-way ANOVAs, 
      Kruskall-Wallis tests, and multivariable regression were used to explore 
      differences between weight loss groups. RESULTS: The majority of patients (66.8%) 
      reported losing weight. Compared to other groups, patients who lost >10 lbs were 
      more likely to be engaged in a weight loss program for at least 6 months. 
      Patients in the Lost >10 lbs and Lost 5-10 lbs groups reported the greatest 
      satisfaction with canagliflozin (p<0.05 for both). Multivariable analyses 
      controlling for patient demographic and treatment characteristics revealed that 
      losing >10 lbs was associated with reduced diabetes distress, improved A1c and 
      blood glucose levels, and decreased perceived frequency of hyperglycemia 
      (p<0.05). CONCLUSION: Increased positive patient outcomes, engagement in diabetes 
      self-management, and medication satisfaction were observed among patients who 
      reported weight loss. These findings suggest that a T2DM regimen that includes 
      canagliflozin as part of a weight loss regimen can help improve patient outcomes 
      and experiences with T2DM.
FAU - Gerlanc, Nicole M
AU  - Gerlanc NM
AD  - Health Analytics, LLC Columbia, MD, USA.
FAU - Cai, Jennifer
AU  - Cai J
AD  - Janssen Scientific Affairs, LLC Titusville, NJ, USA.
FAU - Tkacz, Joseph
AU  - Tkacz J
AD  - Health Analytics, LLC Columbia, MD, USA.
FAU - Bolge, Susan C
AU  - Bolge SC
AD  - Janssen Scientific Affairs, LLC Titusville, NJ, USA.
FAU - Brady, Brenna L
AU  - Brady BL
AD  - Health Analytics, LLC Columbia, MD, USA.
LA  - eng
PT  - Journal Article
DEP - 20170320
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC5365331
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - T2DM
OT  - diabetes self-management
OT  - patient outcomes
OT  - weight management
COIS- Disclosure SCB and JC are the employees of Janssen Scientific Affairs, LLC, and 
      are stockholders in Johnson and Johnson. Study sponsors contributed to study 
      design, interpretation of results, and manuscript development. The other authors 
      report no conflicts of interest in this work.
EDAT- 2017/04/01 06:00
MHDA- 2017/04/01 06:01
PMCR- 2017/03/20
CRDT- 2017/04/01 06:00
PHST- 2017/04/01 06:00 [entrez]
PHST- 2017/04/01 06:00 [pubmed]
PHST- 2017/04/01 06:01 [medline]
PHST- 2017/03/20 00:00 [pmc-release]
AID - dmso-10-089 [pii]
AID - 10.2147/DMSO.S129824 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2017 Mar 20;10:89-99. doi: 10.2147/DMSO.S129824. 
      eCollection 2017.